Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
In a move to increase its presence in immunology and inflammation, the Danish biotech Genmab has launched a collaboration with argenx in the Netherlands to co-discover and co-develop antibody treatments.
Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.
Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, has announced its launch and $101m in Series A financing.
Sanofi and Stanford University School of Medicine have established a three-year research collaboration: focusing on autoimmune diseases and inflammatory conditions.
Thermo Fisher Scientific has announced a new, first-of-its-kind human plasma-like cell culture medium that more closely resembles the natural cellular environment found in the human body to provide researchers with a realistic view of cell growth.
Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.
Antitope will develop a manufacturing cell line for the Baylor Institute for Immunology Research’s (BIIR) novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer.